{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:08:23Z","timestamp":1792120103753,"version":"4.4.0"},"reference-count":49,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-23-1155993-01-MM"],"award-info":[{"award-number":["RSG-23-1155993-01-MM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["ME220215P1"],"award-info":[{"award-number":["ME220215P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT scholar"],"award-info":[{"award-number":["CPRIT scholar"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200520"],"award-info":[{"award-number":["RP200520"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["558998"],"award-info":[{"award-number":["558998"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA240700"],"award-info":[{"award-number":["R01CA240700"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R35GM153387"],"award-info":[{"award-number":["R35GM153387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,9,6]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperactivated protein arginine methyltransferases (PRMTs) are implicated in human cancers. Inhibiting tumor intrinsic PRMT5 was reported to potentiate antitumor immune responses, highlighting the possibility of combining PRMT5 inhibitors (PRMT5i) with cancer immunotherapy. However, global suppression of PRMT5 activity impairs the effector functions of immune cells. Here, we sought to identify strategies to specifically inhibit PRMT5 activity in tumor tissues and develop effective PRMT5i-based immuno-oncology (IO) combinations for cancer treatment, particularly for methylthioadenosine phosphorylase (MTAP)-loss cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Isogeneic tumor lines with and without MTAP loss were generated by CRISPR\/Cas9 knockout. The effects of two PRMT5 inhibitors (GSK3326595 and MRTX1719) were evaluated in these isogenic tumor lines and T cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      . Transcriptomic and proteomic changes in tumors and T cells were characterized in response to PRMT5i treatment. Furthermore, the efficacy of MRTX1719 in combination with immune checkpoint blockade was assessed in two syngeneic murine models with MTAP-loss tumor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GSK3326595 significantly suppresses PRMT5 activity in tumors and T cells regardless of the MTAP status. However, MRTX1719, a methylthioadenosine-cooperative PRMT5 inhibitor, exhibits tumor-specific PRMT5 inhibition in MTAP-loss tumors with limited immunosuppressive effects. Mechanistically, transcriptomic and proteomic profiling analysis reveals that MRTX1719 successfully reduces the activation of the PI3K pathway, a well-documented immune-resistant pathway. It highlights the potential of MRTX1719 to overcome immune resistance in MTAP-loss tumors. In addition, MRTX1719 sensitizes MTAP-loss tumor cells to the killing of tumor-reactive T cells. Combining MRTX1719 and anti-PD-1 leads to superior antitumor activity in mice bearing MTAP-loss tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Collectively, our results provide a strong rationale and mechanistic insights for the clinical development of MRTX1719-based IO combinations in MTAP-loss tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009600","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:00:20Z","timestamp":1727082020000},"page":"e009600","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors"],"prefix":"10.1136","volume":"12","author":[{"given":"Si","family":"Chen","sequence":"first","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakai","family":"Hou","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Jaffery","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjie","family":"Fu","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Shi","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningbo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Bohat","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Egan","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtai","family":"Yu","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Sharif","sequence":"additional","affiliation":[{"name":"Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donjeta","family":"Gjuka","sequence":"additional","affiliation":[{"name":"Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett M","family":"Stone","sequence":"additional","affiliation":[{"name":"Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja Anil","family":"Shah","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon Ahnert","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiping","family":"Chen","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Liu","sequence":"additional","affiliation":[{"name":"Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T","family":"Bedford","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[{"name":"Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-6240","authenticated-orcid":false,"given":"Weiyi","family":"Peng","sequence":"additional","affiliation":[{"name":"Biology and Biochemistry, University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"2025100310250309000_12.9.e009600.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"2025100310250309000_12.9.e009600.2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4161\/cbt.11.7.14948","article-title":"Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity","volume":"11","author":"Bertino","year":"2011","journal-title":"Cancer Biology & Therapy"},{"key":"2025100310250309000_12.9.e009600.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63695-4"},{"key":"2025100310250309000_12.9.e009600.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5214"},{"key":"2025100310250309000_12.9.e009600.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.043"},{"key":"2025100310250309000_12.9.e009600.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5944"},{"key":"2025100310250309000_12.9.e009600.7","doi-asserted-by":"crossref","first-page":"129450","DOI":"10.1016\/j.bmcl.2023.129450","article-title":"Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening","volume":"94","author":"Kalliokoski","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"2025100310250309000_12.9.e009600.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"key":"2025100310250309000_12.9.e009600.9","doi-asserted-by":"crossref","unstructured":"Kim H , Kim H , Feng Y , et al . PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med 2020;12. doi:10.1126\/scitranslmed.aaz5683","DOI":"10.1126\/scitranslmed.aaz5683"},{"key":"2025100310250309000_12.9.e009600.10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.it.2022.03.003","article-title":"All is not lost: learning from 9p21 loss in cancer","volume":"43","author":"Spiliopoulou","year":"2022","journal-title":"Trends Immunol"},{"key":"2025100310250309000_12.9.e009600.11","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7758","article-title":"Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling","volume":"6","author":"Geoghegan","year":"2015","journal-title":"Nat Commun"},{"key":"2025100310250309000_12.9.e009600.12","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040373"},{"key":"2025100310250309000_12.9.e009600.13","doi-asserted-by":"publisher","DOI":"10.1172\/jci131254"},{"key":"2025100310250309000_12.9.e009600.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00159-8"},{"key":"2025100310250309000_12.9.e009600.15","doi-asserted-by":"crossref","DOI":"10.3390\/epigenomes5010002","article-title":"The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma","volume":"5","author":"Wright","year":"2021","journal-title":"Epigenomes"},{"key":"2025100310250309000_12.9.e009600.16","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-1"},{"key":"2025100310250309000_12.9.e009600.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0669"},{"key":"2025100310250309000_12.9.e009600.18","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5\u00b7MTA Complex for the Treatment of MTAP-Deleted Cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"2025100310250309000_12.9.e009600.19","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1158\/1538-7445.AM2023-4970","article-title":"Abstract 4970: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors","volume":"83","author":"Briggs","year":"2023","journal-title":"Cancer Res"},{"key":"2025100310250309000_12.9.e009600.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2022.07.799","article-title":"EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors","volume":"17","author":"Villalona Calero","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025100310250309000_12.9.e009600.21","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1158\/1538-7445.AM2023-6246","article-title":"Abstract 6246: The MTA-cooperative PRMT5 inhibitor AM-9747 exhibits robust antitumor activity in combination with clinically relevant chemotherapies and targeted agents in MTAP null tumor models","volume":"83","author":"Slemmons","year":"2023","journal-title":"Cancer Res"},{"key":"2025100310250309000_12.9.e009600.22","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1158\/1538-7445.AM2023-6272","article-title":"Abstract 6272: AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours","volume":"83","author":"Lynch","year":"2023","journal-title":"Cancer Res"},{"key":"2025100310250309000_12.9.e009600.23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283"},{"key":"2025100310250309000_12.9.e009600.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0712"},{"key":"2025100310250309000_12.9.e009600.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.015"},{"key":"2025100310250309000_12.9.e009600.26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/2326-6066.CIR-21-0614","article-title":"Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses","volume":"10","author":"Fedoriw","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025100310250309000_12.9.e009600.27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt703"},{"key":"2025100310250309000_12.9.e009600.28","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"2025100310250309000_12.9.e009600.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.04.003"},{"key":"2025100310250309000_12.9.e009600.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.026"},{"key":"2025100310250309000_12.9.e009600.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1259"},{"key":"2025100310250309000_12.9.e009600.32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3191"},{"key":"2025100310250309000_12.9.e009600.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"2025100310250309000_12.9.e009600.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"2025100310250309000_12.9.e009600.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.02.024"},{"key":"2025100310250309000_12.9.e009600.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3409"},{"key":"2025100310250309000_12.9.e009600.37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"2025100310250309000_12.9.e009600.38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100310250309000_12.9.e009600.39","doi-asserted-by":"crossref","first-page":"722188","DOI":"10.3389\/fimmu.2021.722188","article-title":"PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"2025100310250309000_12.9.e009600.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.08.007"},{"key":"2025100310250309000_12.9.e009600.41","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1567711"},{"key":"2025100310250309000_12.9.e009600.42","doi-asserted-by":"crossref","first-page":"114842","DOI":"10.1016\/j.ejmech.2022.114842","article-title":"Medicinal chemistry strategies targeting PRMT5 for cancer therapy","volume":"244","author":"Fu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2025100310250309000_12.9.e009600.43","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100310250309000_12.9.e009600.44","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/2159-8290.CD-NB2023-0079","article-title":"AMG 193 Effective in Multiple Tumor Types","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"2025100310250309000_12.9.e009600.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.014"},{"key":"2025100310250309000_12.9.e009600.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23833-2","article-title":"PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis","volume":"12","author":"Yin","year":"2021","journal-title":"Nat Commun"},{"key":"2025100310250309000_12.9.e009600.47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"key":"2025100310250309000_12.9.e009600.48","doi-asserted-by":"crossref","first-page":"953721","DOI":"10.3389\/fimmu.2022.953721","article-title":"Genomic alteration of MTAP\/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100310250309000_12.9.e009600.49","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:25:14Z","timestamp":1759512314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,23]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/jitc-2024-009600"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009600","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}